By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)  

3301 Agriculture Drive

Madison  Wisconsin  53716  U.S.A.
Phone: 608-441-8120 Fax: 608-441-8120


Key Statistics

Ownership: Public

Web Site: Cellectar Biosciences
Symbol: CLRB


Drug Discovery

Company News
After Much Anticipation, Cellectar Biosciences  (CLRB) Initiates NCI-Supported Phase II Trial Of CLR 131 In Multiple Myeloma And Other Blood Cancers 3/30/2017 8:12:16 AM
Cellectar Biosciences  (CLRB) Further Deepens Intellectual Property Portfolio With Patent Grant For PET Imaging PDC 3/21/2017 10:44:35 AM
Cellectar Biosciences  (CLRB) Reports 2016 Company Performance And Continued Progress In First Quarter 2017 3/16/2017 10:36:49 AM
Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences  (CLRB)’ Intellectual Property Portfolio 3/14/2017 8:21:51 AM
Cellectar Biosciences  (CLRB) To Host Conference Call On March 15 To Report Fourth Quarter And Year-End 2016 Financial Results And Corporate Performance 3/9/2017 9:11:10 AM
Expanding Its Strategic Relationship With Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences  (CLRB) Executes New License Agreement 3/8/2017 10:12:50 AM
Cellectar Biosciences  (CLRB) Provides Phase I Trial Update Of CLR 131 In Multiple Myeloma: Median Progression-Free Survival Extends To 133 Days, Median Overall Survival Reaches 17.7 Months 2/27/2017 8:02:35 AM
Upon Successful Completion Of Cohort 3, Cellectar Biosciences  (CLRB) Initiates Fourth Cohort Of Its Phase I Clinical Trial Of CLR 131 In Multiple Myeloma 2/22/2017 10:39:37 AM
Cellectar Biosciences  (CLRB) Announces Two Peer Reviewed Studies Demonstrating The Capabilities Of The PDC Platform 1/31/2017 7:21:22 AM
Cellectar Biosciences  (CLRB) Release: Company Announces Additional U.S. Patent Granted For CLR 131 And CLR 125 In A Broad Range Of Solid Tumors 1/24/2017 7:17:19 AM